Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
Cash Flows From Operating Activities | |||||
Net Income | 2,242,900 | 5,240,400 | 3,050,700 | 3,108,100 | 1,344,900 |
Depreciation Amortization | 400,600 | 1,527,300 | 1,139,600 | 728,600 | 362,300 |
Income taxes - deferred | -279,000 | -2,341,000 | -1,834,800 | -990,500 | -559,400 |
Accounts receivable | N/A | -2,451,000 | N/A | N/A | N/A |
Accounts payable and accrued liabilities | N/A | 4,274,400 | N/A | N/A | N/A |
Other Working Capital | -1,751,200 | -3,055,000 | 103,200 | -676,100 | 164,100 |
Other Operating Activity | 552,700 | 1,045,000 | 2,093,300 | 192,400 | 418,700 |
Operating Cash Flow | $1,166,000 | $4,240,100 | $4,552,000 | $2,362,500 | $1,730,600 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 17,000 | 94,000 | 76,000 | 49,800 | 38,500 |
PPE Investments | -986,300 | -3,447,600 | -2,377,000 | -1,406,700 | -668,500 |
Net Acquisitions | N/A | -1,044,300 | N/A | N/A | N/A |
Purchase Of Investment | -117,100 | -730,800 | -474,800 | -343,400 | -146,000 |
Sale Of Investment | 70,500 | 508,100 | 476,200 | 388,400 | 281,900 |
Purchase Sale Intangibles | N/A | N/A | 1,604,300 | N/A | N/A |
Other Investing Activity | -161,700 | -2,532,100 | -1,928,800 | 164,000 | -194,700 |
Investing Cash Flow | $-1,177,600 | $-7,152,700 | $-4,228,400 | $-1,147,900 | $-688,800 |
Cash Flows From Financing Activities | |||||
Change In Short Term Borrowing | -5,204,800 | N/A | 97,000 | -1,498,000 | -1,498,000 |
Debt Issued | 6,452,500 | 8,649,900 | 3,958,500 | 3,958,500 | 3,958,500 |
Common Stock Repurchased | N/A | -750,000 | -750,000 | -750,000 | -750,000 |
Dividend Paid | -1,169,200 | -4,069,300 | -3,051,200 | -2,035,000 | -1,017,200 |
Other Financing Activity | -389,800 | -335,000 | -303,400 | -296,600 | -281,000 |
Financing Cash Flow | $-311,300 | $3,495,600 | $-49,100 | $-621,100 | $412,300 |
Exchange Rate Effect | -35,500 | 168,600 | 39,300 | 34,000 | 24,800 |
Beginning Cash Position | 2,818,600 | 2,067,000 | 2,067,000 | 2,067,000 | 2,067,000 |
End Cash Position | 2,460,200 | 2,818,600 | 2,380,800 | 2,694,500 | 3,545,900 |
Net Cash Flow | $-358,400 | $751,600 | $313,800 | $627,500 | $1,478,900 |
Free Cash Flow | |||||
Operating Cash Flow | 1,166,000 | 4,240,100 | 4,552,000 | 2,362,500 | 1,730,600 |
Capital Expenditure | -986,300 | -3,447,600 | -2,377,000 | -1,406,700 | -668,500 |
Free Cash Flow | 179,700 | 792,500 | 2,175,000 | 955,800 | 1,062,100 |